Your situation (severe hypercholesterolemia short-circuits the risk score) CKD stage 3–4, age 40–75
ckd-statinNo one has reached this rule yetModerate-intensity statin (± ezetimibe) on the diagnosis alone; LDL-C <100
No clinician has signed off this rule yet. It reflects our reading of the guidelines cited below, which has not been independently checked.
Word for word, as generated for the example person below. Figures in the text are theirs.
Your kidney function alone is a reason to be on lipid-lowering treatment — a moderate-intensity statin, or a statin plus ezetimibe. Target LDL-C below 100 mg/dL (and non-HDL-C below 130).
Chronic kidney disease at your level (eGFR 58, stage 3) between ages 40 and 75 is an independent indication in the 2026 guideline, in the same way diabetes is — the risk calculator does not have to agree. Kidney disease raises cardiovascular risk out of proportion to what a lipid panel suggests, and people with it are consistently under-treated.
Guideline consensusRecommended by the guideline writing committee, drawing on trials plus expert judgement where trials run out.· Class I· checked 2026-09-12
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia · Class I
“Heart failure with a weak pump” — an illustrative profile, not a real user.
Asked after: No known cardiovascular disease
Then asks: Coronary artery calcium (CAC) score? (further testing beyond basic labs)
Cited by the recommendations above.
For practising clinicians. Endorse it, propose a change, or dispute it. We verify every reviewer before a review is shown, and a review stays attached to the version of the rule you saw — if the rule changes, the page says so. You'll be asked to declare any relevant interests; they're shown with your review.
Log in or create an account to submit a review. An account is how we tie a review to a person we can verify.
Runs in lib/engine/lipidPathway.ts as ckd-statin.